Drug intelligence / Profile preview

FE 999322

Development stage: Discontinued
Lead developer: Ferring Pharmaceuticals
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

**FE 999322** is an investigational microbiome-based therapeutic from Ferring Pharmaceuticals developed as a **microbiota suspension** for the treatment of **ulcerative colitis**. Public trial records describe it as a fecal microbiota transplant style product intended to modulate the intestinal microbial community rather than act through a single defined molecular target. In a registered Phase 1b proof-of-concept study, FE 999322 was being evaluated versus placebo in adults with mild to moderate ulcerative colitis, alongside the oral capsule program FE 999324; the study was later listed as withdrawn. The asset appears to be an early-stage **microbiome therapy / live biotherapeutic-style product** administered as a suspension, with mechanism framed around restoration or alteration of gut microbiome composition and downstream effects on mucosal inflammation.

Other names: microbiota suspensionfecal microbiota transplant

Beyond the preview

Go deeper on FE 999322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FE 999322.

Explore the full profile